Eli Lilly and Company (SWX:LLY)

Switzerland flag Switzerland · Delayed Price · Currency is CHF
795.00
+15.00 (1.92%)
At close: Jan 30, 2026
8.90%
Market Cap715.96B +16.8%
Revenue (ttm)47.38B +45.4%
Net Income14.68B +120.0%
EPS16.30 +121.0%
Shares Outn/a
PE Ratio48.77
Forward PE32.65
Dividend5.01 (0.63%)
Ex-Dividend DateNov 14, 2025
Volumen/a
Average Volume3
Openn/a
Previous Close780.00
Day's Rangen/a
52-Week Range538.08 - 880.00
Beta0.33
RSI40.68
Earnings DateFeb 4, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja... [Read more]

Industry Drug Manufacturers - General
Sector Healthcare
Founded 1876
Employees 47,000
Stock Exchange SIX Swiss Exchange
Ticker Symbol LLY
Full Company Profile

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD Financial Statements

News

Eli Lilly: Obesity Pricing For Access Tradeoff A Net Positive

Eli Lilly enters 2026 with strong commercial momentum, pipeline wins, and shares near all-time highs. The company's strategic price cuts for Zepbound and commitment to a low-priced launch of orforglip...

1 day ago - Seeking Alpha

Eli Lilly Teams Up With Two Biotechs To Target Autoimmune Disease, Hearing Loss In Deals Worth $3 Billion

Repertoire Immune Medicines entered a strategic collaboration on Thursday with Eli Lilly and Co. (NYSE: LLY) to develop tolerizing therapies for multiple autoimmune diseases.

1 day ago - Benzinga

Trump says Eli Lilly to build six US plants

U.S. President Donald Trump said on Thursday that he has spoken to the head of pharmaceutical company Eli Lilly and that the company plans to build six plants in the country.

1 day ago - Reuters

Prediction: Artificial Intelligence (AI) Will Reshape This Industry by 2030. This Stock Could Lead.

AI could make it faster and easier to develop drugs. Eli Lilly is looking to lead this transformation.

1 day ago - The Motley Fool

Lilly signs up to $1.93 billion deal with Repertoire for autoimmune therapies

Drugmaker Eli Lilly is partnering with Repertoire Immune Medicines in a deal worth up to $1.93 billion to develop therapies for multiple autoimmune diseases, the Massachusetts-based biotech said on Th...

2 days ago - Reuters

Eli Lilly signs up to $1.12 billion deal with private gene-editing firm Seamless

U.S. drugmaker Eli Lilly signed an agreement worth up to $1.12 billion with Seamless Therapeutics, the Germany-based startup said on Wednesday, to develop and commercialize treatments for hearing loss...

3 days ago - Reuters

Exclusive: Novo's Wegovy and Ozempic US advertising spend doubles rival Eli Lilly, data shows

Novo Nordisk spent nearly $500 million on U.S. advertising for its GLP-1 drugs Wegovy and Ozempic in the first nine months of 2025, more than double what Eli Lilly shelled out for its rival medicines,...

3 days ago - Reuters

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

The U.S. Centers for Medicare & Medicaid Services on Tuesday named a new group of branded drugs from major pharmaceutical companies including Eli Lilly , Pfizer and AbbVie for the third cycle of the M...

3 days ago - Reuters

Up 36%, Is Eli Lilly Still a Buy?

Eli Lilly is at the forefront of both diabetes and obesity medications. The pharmaceutical giant has offered strong guidance for the end of 2025.

3 days ago - The Motley Fool

Where Will Eli Lilly Be in 10 Years?

The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle.

3 days ago - The Motley Fool

Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker?

Both companies may succeed in this industry.

4 days ago - The Motley Fool

A Look Into Eli Lilly and Co Inc's Price Over Earnings

Looking into the current session, Eli Lilly and Co Inc. (NYSE: LLY) shares are trading at $1060.01, after a 0.40% drop. Over the past month, the stock decreased by 1.76% , but over the past year, it ...

4 days ago - Benzinga

Lansing Street Advisors Sells 138 Shares of Eli Lilly and Co (LLY)

Lansing Street Advisors Sells 138 Shares of Eli Lilly and Co (LLY)

4 days ago - GuruFocus

BCS Wealth Management Sells 655 Shares of Eli Lilly and Co (LLY)

BCS Wealth Management Sells 655 Shares of Eli Lilly and Co (LLY)

4 days ago - GuruFocus

Code Waechter LLC Buys 115 Shares of Eli Lilly and Co (LLY)

Code Waechter LLC Buys 115 Shares of Eli Lilly and Co (LLY)

4 days ago - GuruFocus

Foster Victor Wealth Advisors, LLC Buys 1,127 Shares of Eli Lilly and Co (LLY)

Foster Victor Wealth Advisors, LLC Buys 1,127 Shares of Eli Lilly and Co (LLY)

4 days ago - GuruFocus

Reyes Financial Architecture, Inc. Buys 179 Shares of Eli Lilly and Co (LLY)

Reyes Financial Architecture, Inc. Buys 179 Shares of Eli Lilly and Co (LLY)

4 days ago - GuruFocus

SeaBridge Investment Advisors LLC Buys 237 Shares of Eli Lilly and Co (LLY)

SeaBridge Investment Advisors LLC Buys 237 Shares of Eli Lilly and Co (LLY)

4 days ago - GuruFocus

My Top AI Healthcare Stock to Buy and Hold for 20 Years

Eli Lilly has made several moves to boost its artificial intelligence (AI) capacity. It could help complement its strong innovative capabilities.

5 days ago - The Motley Fool

Should You Dump Eli Lilly's Shares After This Setback?

The company got some bad news to start 2026.

6 days ago - The Motley Fool

Goldman Sachs Strategic Factor Allocation Fund Buys 13,479 Shares of Eli Lilly and Co (LLY)

Goldman Sachs Strategic Factor Allocation Fund Buys 13,479 Shares of Eli Lilly and Co (LLY)

6 days ago - GuruFocus

Ventyx Biosciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Ventyx Biosciences, Inc. - VTYX

NEW YORK and NEW ORLEANS, Jan. 23, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.

7 days ago - PRNewsWire

Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead?

Eli Lilly's valuation has been driven higher by investor excitement around GLP-1 drugs, leaving other drugmakers languishing.

7 days ago - The Motley Fool

Novo's 500% Pill Pop: Wegovy Just Obliterated Every GLP-1 Launch Record

Novo Nordisk A/S ' (NYSE: NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week o...

7 days ago - Benzinga